Novo Nordisk A/s

Novozymes A/s

Ascendis Pharma Endocrinology Division A/s

Maxygen Aps

Other

Maxygen Holdings Ltd.

Ascendis Pharma Growth Disorders Division A/s

Novozymeo A/s

Maxygen, Inc.

Grethe Norskov Rasmussen

Torben Halkier

Egon Nielsen

Allan Svendsen

Harald Rau

Joel R Cherry

Ulrich Hersel

Palle Schneider

Thomas Wegge

Anders Hjelholt Pedersen

Lisbeth Bech

Martin Schulein

Susanne Kindermann

Lene Nonboe Andersen

Markus Sakari Kauppinen

Kim Vilbour Andersen

Kennett Sprogøe

Claus Bornaes

Thomas Sandal

Peter Rosholm

Lotte Rugholm Henriksen

Poul Baad Rasmussen

Kennett Sprogoe

Mariko Okada

Bobby Soni

Carsten Germansen

Torben Leßmann

Torben Lebmann

Henrik Fredholm

Carsten Mailand Hjorth

Shamkant Anant Patkar

Sven Hastrup

Jan Lehmbeck

Carsten Mailand Hjort

Niels Henrik Sorensen

Fred Hagen

Niels Henrik So Slashedrensen

Jan Mo Mikkelsen

Iben Angelica No Slashedrrevang

Kaj Andre Holm

Jens To Andersen

Iben Angelica N&oslash;rrevang

Thomas Schafer

Jens T&oslash;nne Andersen

Thomas Sch&auml;fer

Susanne Kinderman

Martin Schuelein

A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.

PEGylated recombinant human growth hormone compounds

PEGylated Recombinant Human Growth Hormone Compounds

A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to an elevated pH of above 8.0 for a period of time suitable to remove PEG moieties attached to a hydroxyl group, and reducing the pH to about 8.0 or lower; as well as PEGylated G-CSF polypeptides and compositions produced according to the method and methods for increasing neutrophil levels in a patient using the PEGylated G-CSF polypeptides and compositions.

Compositions comprising positional isomers of PEGylated G-CSF

The invention relates to a conjugate exhibiting interferon &#x3b2; (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.

Interferon beta-like molecules

Compositions comprising mixtures of positional PEG isomers of PEGylated G-CSF

Interferon &#x3b2; variants and conjugates

The present invention relates to transglutaminases and transglutaminase preparations obtained from lower fungi belonging to the class Oomycetes and unprecedented high-level expression is achievable by growing these coenocytium forming organisms, especially the strainssp.,(or),and; and a recombinant transglutaminase has been cloned and expressed, the enzyme and enzyme preparations being useful for cross-linking proteins, e.g. in flour, baked products, meat products, fish products, cosmetics, cheese, milk products, gelled food products and leather finishing, or as a glutaminase, e.g. in bread and other baked glutein-containing food products.

Transglutaminase from oomycetes

The present invention relates to a storage-stable liquid formulation comprising a laccase comprising (i) a laccase, (ii) at least one polyalcohol, which formulation has a pH which is more alkaline than the pH optimum of the laccase. It is also an object of the invention to provide a method for improving the storage-stability of liquid formulations comprising a laccase and the use of said liquid formulations for a personal care application or for bleaching or for textile applications such as dyeing of fabrics.

Storage-stable liquid formulation comprising a laccase

The present invention relates to transglutaminases and transglutaminase preparations obtained from lower fungi belonging to the class Oomycetes. Unprecedented high-level expression is achievable by growing these coenocytium forming organisms, especially the strains Pythium sp., (or ), and . Arecombinant transglutaminase has been cloned and expressed, the enzyme and enzyme preparations being useful for cross-linking proteins, e.g. in flour, baked products, meat products, fish products, cosmetics, cheese, milk products, gelled food products and leather finishing, or as a glutaminase, e.g. in bread and other baked glutein-containing food products.

The present invention relates to a method of designing laccase mutants with improved stability properties, which method is based on the hitherto unknown three-dimensional structure of,laccase.

Laccase mutants

A method for identifying a transglutaminase-producing microorganism based on a selective assay is disclosed.

Microbial transglutaminases, their production and use

The present invention relates to a method of designing laccase mutants with improved stability properties, which method is based on the hitherto unknown three-dimensional structure of Coprinus cinereus laccase.

Growing community of inventors

Farum, Denmark

Grethe Norskov Rasmussen